Premium
Rare mutations and no hypermethylation at the CDKN2A locus in epithelial ovarian tumours
Author(s) -
Shih YangChia,
Kerr Judith,
Liu Jim,
Hurst Terry,
Khoo SooKeat,
Ward Bruce,
Wainwright Brandon,
ChenevixTrench Georgia
Publication year - 1997
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/(sici)1097-0215(19970304)70:5<508::aid-ijc3>3.0.co;2-1
Subject(s) - cdkn2a , biology , cancer research , ovarian cancer , loss of heterozygosity , tumor suppressor gene , locus (genetics) , gene , cancer , carcinogenesis , genetics , allele
The tumour‐suppressor gene CDKN2A ( p16, MTS1, CDK4I ) encodes a cell cycle‐regulatory protein and is located on chromosome 9p21, a region deleted in a wide variety of human cancers. To determine the role of the CDKN2A gene in the development of ovarian adenocarcinomas, we examined a large series of benign, low malignant potential (LMP) and invasive ovarian neoplasms for evidence of loss of heterozygosity (LOH), homozygous deletions, point mutations and hypermethylation of the CDKN2A locus. We have previously reported LOH on 9p in 45% of malignant ovarian neoplasms and a smaller percentage of benign and LMP tumours. In the current study, 6 malignant tumours were identified with partial deletions of 9p21. In 5 of these, the CDKN2A gene lays within the minimal deleted region. Homozygous deletions of CDKN2A were observed in only 2/88 invasive ovarian tumours and in 5/11 ovarian cancer cell lines. Of 15 primary ovarian tumours analyzed, one nonsense mutation was identified in a mucinous LMP tumour. No evidence of hypermethylation of the CDKN2A gene was found in 50 primary ovarian adenocarcinomas nor in 3 ovarian cancer cell lines. In conclusion, homozygous deletions, mutations and the de novo methylation of 5′ CpG island are not frequent modes of inactivation of the CDKN2A gene in ovarian cancer. The target of 9p LOH in ovarian adenocarcinomas is therefore unknown. Int. J. Cancer 70:508–511. © 1997 Wiley‐Liss Inc.